Cantitate/Preț
Produs

Considering the Patient in Pediatric Drug Development: How Good Intentions Turned Into Harm

Autor Klaus Rose
en Limba Engleză Paperback – 20 noi 2020
Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term "children" is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union's (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term "child."
In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs as well as key differences between newborns, infants, older children and adolescents.


  • Explains relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs, including key differences between newborns, infants, older children and adolescents
  • Discusses historical roots of separate drug approval in officially labeled "children" and conflicts of interest in performing and publishing "pediatric" research
  • Helps to decipher justifications for pediatric studies to help people navigate the relevance of the information
Citește tot Restrânge

Preț: 68901 lei

Preț vechi: 91572 lei
-25% Nou

Puncte Express: 1034

Preț estimativ în valută:
13185 13688$ 10995£

Carte tipărită la comandă

Livrare economică 15-29 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780128238882
ISBN-10: 0128238887
Pagini: 414
Dimensiuni: 152 x 229 x 24 mm
Greutate: 0.55 kg
Editura: ELSEVIER SCIENCE

Cuprins

Rumpelstiltskin and the miller’s daughterConclusion and outlook Introduction Abbreviations and technical explanations Background 1. The process of modern drug development and the challenge of young patients 2. US and EU pediatric legislation 3. A paradigm shift 4. Introduction: specific disease areas 4.1 Tissue-engineered products (TEPs), advanced medicinal4.2 Suicide, depression, and mental disorders in young4.3 Cancer and malignancies in young patients4.4 Chronic arthritis in young and adult patients, and “Juvenile Idiopathic Arthritis” (JIA)4.5 Diabetes4.6 Allergies and allergen-specific immunotherapy (ASIT) in young patients4.7 Epilepsy4.8 Multiple sclerosis4.9 Atopic dermatitis and psoriasis4.10 Cystic fibrosis4.11 Vaccines and antiinfectives5. Neonatology 6. Challenges at the interface of science, drug development, and drug approval beyond specific disease areas 6.1 The on-label/off-label framework in adults and young patients6.2 Developmental pharmacology and the globalization of the children-are-therapeutic-orphans mantra6.3 Extrapolation6.4 Daily deceit in “pediatric” studies6.5 Myths in today’s medical world and “pediatric” studies7. Juvenile animal studies8. Child-friendly formulations: tablets, quick-dissolving formulations, liquids, and more9. What do young patients really need?

Recenzii

"The book is educational and interesting. As a pharmacist who worked in a pediatric hospital for five years, I do think the book could have discussed some of the life-saving efforts of pediatric medicine as well." --© Doody’s Review Service, 2020, Judith Klevan, BA, BS(Einstein Medical Center Philadelphia), reviewer, expert opinion